成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 73724-45-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 73724-45-5
Chemical Structure| 73724-45-5
Structure of 73724-45-5 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 73724-45-5 ]

Related Doc. of [ 73724-45-5 ]

Alternatived Products of [ 73724-45-5 ]
Product Citations

Product Citations

Agrawal, Anushka ; Euliano, Erin M ; Pogostin, Brett H , et al. DOI:

Abstract: Introduction Multidomain peptides (MDPs) are amino acid sequences that self-assemble to form supramolecular hydrogels under physiological conditions that have shown promise for a number of biomedical applications. K2(SL)6K2 (“K2”), a widely studied MDP, has demonstrated the ability to enhance the humoral immune response to co-delivered antigen. Herein, we sought to explore the in vitro and in vivo properties of a peptide with the same sequence but opposite chirality (D-K2) since peptides composed of D-amino acids are resistant to protease degradation and potentially more immunostimulatory than their canonical counterparts. Methods K2 and D-K2 hydrogels were characterized and evaluated in vitro using circular dichroism, rheology, cryo-electron microscopy, and fuorescence recovery after photobleaching studies. In vivo experiments in SKH-1 mice were conducted to evaluate both ovalbumin release from the hydrogels and hydrogel degradation. The injection site of the hydrogels was analyzed using histology and humoral immunity was assessed by ELISA. Results In vitro, the enantiomeric hydrogels exhibited similar rheological properties, and fuorescence recovery after pho_x005f_x0002_tobleaching experiments demonstrated that the difusion of ovalbumin (OVA), a model antigen, was similar within both hydrogels. In vivo, K2 and D-K2 peptide hydrogels had similar OVA release rates, both releasing 89% of the antigen within 8 days. Both hydrogels elicited a similar antigen-specifc humoral immune response. However, the in vivo degradation of the D-K2 hydrogel progressed signifcantly slower than K2. After 4 weeks in vivo, only 23±7% of the K2 hydrogel remained at the injection site compared to 94±7% of the D-K2 hydrogel, likely due to their diferent protease susceptibilities. Conclusion Taken together, these data suggest that peptide chirality can be a useful tool for increasing hydrogel residence time for biomedical applications that would beneft from long persistence times and that, if an antigen releases over a suf_x005f_x0002_fciently short period, release can be largely independent of degradation rate, though slower-difusing payloads may exhibit degradation rate dependence.

Keywords: Hydrogel ; Chirality ; Degradation ; Drug delivery ; Peptides ; Adjuvants

Purchased from AmBeed: ; ; ; ;

Product Details of [ 73724-45-5 ]

CAS No. :73724-45-5 MDL No. :MFCD00051928
Formula : C18H17NO5 Boiling Point : -
Linear Structure Formula :- InChI Key :-
M.W : 327.33 Pubchem ID :-
Synonyms :

Calculated chemistry of [ 73724-45-5 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 24
Num. arom. heavy atoms : 12
Fraction Csp3 : 0.22
Num. rotatable bonds : 7
Num. H-bond acceptors : 5.0
Num. H-bond donors : 3.0
Molar Refractivity : 86.33
TPSA : 95.86 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.88 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.0
Log Po/w (XLOGP3) : 2.0
Log Po/w (WLOGP) : 1.97
Log Po/w (MLOGP) : 1.51
Log Po/w (SILICOS-IT) : 1.93
Consensus Log Po/w : 1.88

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.56

Water Solubility

Log S (ESOL) : -3.04
Solubility : 0.3 mg/ml ; 0.000917 mol/l
Class : Soluble
Log S (Ali) : -3.64
Solubility : 0.075 mg/ml ; 0.000229 mol/l
Class : Soluble
Log S (SILICOS-IT) : -4.33
Solubility : 0.0153 mg/ml ; 0.0000469 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 0.0
Synthetic accessibility : 3.7

Safety of [ 73724-45-5 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 73724-45-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 73724-45-5 ]

[ 73724-45-5 ] Synthesis Path-Downstream   1~10

  • 1
  • [ 159610-89-6 ]
  • Nα-Fmoc-Arg(NG-pbf)-Rink amide resin [ No CAS ]
  • [ 29022-11-5 ]
  • [ 35661-60-0 ]
  • [ 108-24-7 ]
  • [ 71989-23-6 ]
  • [ 73724-45-5 ]
  • [ 71989-20-3 ]
  • [ 75932-02-4 ]
  • [ 198561-07-8 ]
  • [ 1217266-32-4 ]
  • 2
  • Nα-Fmoc-Arg(NG-pbf)-Rink amide resin [ No CAS ]
  • [ 1097192-04-5 ]
  • [ 29022-11-5 ]
  • [ 35661-60-0 ]
  • [ 108-24-7 ]
  • [ 71989-23-6 ]
  • [ 73724-45-5 ]
  • [ 71989-20-3 ]
  • [ 75932-02-4 ]
  • [ 198561-07-8 ]
  • [ 1217266-30-2 ]
  • 3
  • Nα-Fmoc-Arg(NG-pbf)-Rink amide resin [ No CAS ]
  • [ 1097192-04-5 ]
  • [ 29022-11-5 ]
  • [ 35661-60-0 ]
  • [ 108-24-7 ]
  • [ 71989-23-6 ]
  • [ 73724-45-5 ]
  • [ 71989-20-3 ]
  • [ 75932-02-4 ]
  • [ 198561-07-8 ]
  • [ 1217266-28-8 ]
  • 4
  • [ 29022-11-5 ]
  • [ 68858-20-8 ]
  • [ 104091-09-0 ]
  • [ 35737-15-6 ]
  • [ 73731-37-0 ]
  • [ 71989-16-7 ]
  • [ 105047-45-8 ]
  • [ 73724-45-5 ]
  • [ 198561-07-8 ]
  • [ 684270-46-0 ]
  • C58H90N20O18 [ No CAS ]
  • 5
  • [ 942518-20-9 ]
  • [ 29022-11-5 ]
  • [ 68858-20-8 ]
  • [ 104091-09-0 ]
  • [ 35737-15-6 ]
  • [ 73731-37-0 ]
  • [ 71989-16-7 ]
  • [ 105047-45-8 ]
  • [ 73724-45-5 ]
  • [ 198561-07-8 ]
  • C59H92N20O18 [ No CAS ]
  • 6
  • [ 1097192-04-5 ]
  • [ 29022-11-5 ]
  • [ 68858-20-8 ]
  • [ 104091-09-0 ]
  • [ 35737-15-6 ]
  • [ 73731-37-0 ]
  • [ 71989-16-7 ]
  • [ 105047-45-8 ]
  • [ 73724-45-5 ]
  • [ 198561-07-8 ]
  • C60H94N20O18 [ No CAS ]
  • 7
  • [ 29022-11-5 ]
  • [ 35661-60-0 ]
  • [ 35661-39-3 ]
  • 4-chloro-7-nitro-1,2,3-benzoxadiazole [ No CAS ]
  • [ 112883-29-1 ]
  • [ 35661-40-6 ]
  • [ 71989-23-6 ]
  • [ 35737-15-6 ]
  • [ 73731-37-0 ]
  • [ 71989-16-7 ]
  • [ 73724-45-5 ]
  • [ 91000-69-0 ]
  • [ 116611-64-4 ]
  • [ 198561-07-8 ]
  • NBD-HGLASTLTRWAHYNALIRAF-PrA-CONH<SUB>2</SUB> [ No CAS ]
  • 8
  • [ 29022-11-5 ]
  • [ 35661-60-0 ]
  • [ 112883-29-1 ]
  • [ 35661-40-6 ]
  • [ 71989-23-6 ]
  • [ 35737-15-6 ]
  • [ 73731-37-0 ]
  • [ 71989-16-7 ]
  • [ 73724-45-5 ]
  • [ 91000-69-0 ]
  • [ 116611-64-4 ]
  • N-α-Fmoc-L-alanine-3,3,3-d3 [ No CAS ]
  • [ 198561-07-8 ]
  • HGLASTLTRWAHYNALIRAF-PrA-CONH<SUB>2</SUB> [ No CAS ]
  • 9
  • [ 159610-89-6 ]
  • [ 35661-39-3 ]
  • [ 73724-45-5 ]
  • [ 199110-64-0 ]
  • [ 198561-07-8 ]
  • C47H49N8O9Pol [ No CAS ]
  • 10
  • [ 35661-39-3 ]
  • [ 122889-11-6 ]
  • [ 71989-23-6 ]
  • [ 73724-45-5 ]
  • C28H45N5O8 [ No CAS ]
Recommend Products
Same Skeleton Products

Technical Information

Historical Records
; ;